122 related articles for article (PubMed ID: 31767149)
1. Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis.
Zhou S; Zhu X; Liu W; Cheng F; Zou P; You Y; Xiao Y; Guo A; Zhu X
Biochem Biophys Res Commun; 2020 Feb; 522(2):362-367. PubMed ID: 31767149
[TBL] [Abstract][Full Text] [Related]
2. Flow Cytometry Assessment of CD26
Raspadori D; Pacelli P; Sicuranza A; Abruzzese E; Iurlo A; Cattaneo D; Gozzini A; Galimberti S; Baratè C; Pregno P; Nicolosi M; Sorà F; Annunziata M; Luciano L; Caocci G; Moretti S; Sgherza N; Fozza C; Russo S; Usala E; Liberati MA; Ciofini S; Trawinska MM; Gozzetti A; Bocchia M
Cytometry B Clin Cytom; 2019 Jul; 96(4):294-299. PubMed ID: 30714299
[TBL] [Abstract][Full Text] [Related]
3. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia.
Sharma P; Sachdeva MUS; Naseem S; Sreedharanunni S; Das R; Malhotra P; Varma N
Int J Lab Hematol; 2022 Jun; 44(3):518-523. PubMed ID: 35142061
[TBL] [Abstract][Full Text] [Related]
4. Residual Peripheral Blood CD26
Bocchia M; Sicuranza A; Abruzzese E; Iurlo A; Sirianni S; Gozzini A; Galimberti S; Aprile L; Martino B; Pregno P; Sorà F; Alunni G; Fava C; Castagnetti F; Puccetti L; Breccia M; Cattaneo D; Defina M; Mulas O; Baratè C; Caocci G; Sica S; Gozzetti A; Luciano L; Crugnola M; Annunziata M; Tiribelli M; Pacelli P; Ferrigno I; Usala E; Sgherza N; Rosti G; Bosi A; Raspadori D
Front Oncol; 2018; 8():194. PubMed ID: 29900128
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
6. miRNome profiling of LSC-enriched CD34
Ruiz MS; Sánchez MB; Bonecker S; Furtado C; Koile D; Yankilevich P; Cranco S; Custidiano MDR; Freitas J; Moiraghi B; Pérez MA; Pavlovsky C; Varela AI; Ventriglia V; Sánchez Ávalos JC; Larripa I; Zalcberg I; Mordoh J; Valent P; Bianchini M
Front Pharmacol; 2020; 11():612573. PubMed ID: 33569005
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
8. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
9. CD26 expression on circulating CD34+/CD38- progenitor population is a specific and reliable tool for the rapid flow cytometric diagnosis of chronic myeloid leukemia-A single-center validation study.
Rahman K; Singh MK; Chandra D; Gupta R; Sarkar MK; Gupta P; Gupta A; Yadav S; Kashyap R; Nityanand S
Int J Lab Hematol; 2022 Jun; 44(3):524-530. PubMed ID: 35315228
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
Abraham SA; Hopcroft LE; Carrick E; Drotar ME; Dunn K; Williamson AJ; Korfi K; Baquero P; Park LE; Scott MT; Pellicano F; Pierce A; Copland M; Nourse C; Grimmond SM; Vetrie D; Whetton AD; Holyoake TL
Nature; 2016 Jun; 534(7607):341-6. PubMed ID: 27281222
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing CML LSCs from HSCs using CD26.
Jiang X
Blood; 2014 Jun; 123(25):3851-2. PubMed ID: 24948622
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
Culen M; Borsky M; Nemethova V; Razga F; Smejkal J; Jurcek T; Dvorakova D; Zackova D; Weinbergerova B; Semerad L; Sadovnik I; Eisenwort G; Herrmann H; Valent P; Mayer J; Racil Z
Oncotarget; 2016 May; 7(22):33016-24. PubMed ID: 27145281
[TBL] [Abstract][Full Text] [Related]
13. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
Wang Z; Chen CC; Chen W
Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD25 on leukemic stem cells in BCR-ABL1
Sadovnik I; Herrmann H; Eisenwort G; Blatt K; Hoermann G; Mueller N; Sperr WR; Valent P
Exp Hematol; 2017 Jul; 51():17-24. PubMed ID: 28457753
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
[TBL] [Abstract][Full Text] [Related]
16. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
17. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
Valent P; Sadovnik I; Ráčil Z; Herrmann H; Blatt K; Cerny-Reiterer S; Eisenwort G; Lion T; Holyoake T; Mayer J
Eur J Clin Invest; 2014 Dec; 44(12):1239-45. PubMed ID: 25371066
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.
Zhang H; Li S
Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480
[TBL] [Abstract][Full Text] [Related]
19. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
20. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
